Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGTX NASDAQ:ENTA NASDAQ:IPHA NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$1.61+4.5%$1.45$0.22▼$3.83$118.37M1.294.95 million shs5.08 million shsENTAEnanta Pharmaceuticals$7.45-0.1%$7.85$4.09▼$13.37$159.28M0.84270,567 shs179,209 shsIPHAInnate Pharma$2.08$2.05$1.29▼$3.51$191.74M0.2295,011 shs47,815 shsVRCAVerrica Pharmaceuticals$4.41-10.7%$6.33$3.82▼$20.01$41.66M1.7842,975 shs118,344 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-29.03%-35.83%0.00%+450.00%+156.62%ENTAEnanta Pharmaceuticals-9.90%-16.27%-6.75%+5.82%-39.98%IPHAInnate Pharma+3.25%+1.23%-3.28%+10.43%-8.63%VRCAVerrica Pharmaceuticals+4.00%-2.37%-17.11%-22.99%-74.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$1.61+4.5%$1.45$0.22▼$3.83$118.37M1.294.95 million shs5.08 million shsENTAEnanta Pharmaceuticals$7.45-0.1%$7.85$4.09▼$13.37$159.28M0.84270,567 shs179,209 shsIPHAInnate Pharma$2.08$2.05$1.29▼$3.51$191.74M0.2295,011 shs47,815 shsVRCAVerrica Pharmaceuticals$4.41-10.7%$6.33$3.82▼$20.01$41.66M1.7842,975 shs118,344 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-29.03%-35.83%0.00%+450.00%+156.62%ENTAEnanta Pharmaceuticals-9.90%-16.27%-6.75%+5.82%-39.98%IPHAInnate Pharma+3.25%+1.23%-3.28%+10.43%-8.63%VRCAVerrica Pharmaceuticals+4.00%-2.37%-17.11%-22.99%-74.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics 3.25Buy$2.8368.15% UpsideENTAEnanta Pharmaceuticals 3.00Buy$20.20166.32% UpsideIPHAInnate Pharma 3.00Buy$11.00432.43% UpsideVRCAVerrica Pharmaceuticals 2.20Hold$80.001,573.64% UpsideCurrent Analyst Ratings BreakdownLatest VRCA, CGTX, ENTA, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025ENTAEnanta PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $12.009/2/2025ENTAEnanta PharmaceuticalsWestpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$24.008/12/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$24.00 ➝ $25.008/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.007/28/2025IPHAInnate PharmaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy7/28/2025ENTAEnanta PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.006/26/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/AENTAEnanta Pharmaceuticals$67.64M2.40N/AN/A$6.08 per share1.25IPHAInnate Pharma$12.62M15.09N/AN/A$0.11 per share18.78VRCAVerrica Pharmaceuticals$14.70M3.07N/AN/A($1.07) per share-4.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$33.97M-$0.67N/AN/AN/AN/A-251.23%-130.75%11/12/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.32N/AN/AN/A-141.98%-89.02%-27.28%11/24/2025 (Estimated)IPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)VRCAVerrica Pharmaceuticals-$76.58M-$8.28N/AN/AN/AN/AN/A-115.48%11/3/2025 (Estimated)Latest VRCA, CGTX, ENTA, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025VRCAVerrica Pharmaceuticals-$0.70$0.02+$0.72$0.02$4.37 million$12.70 million8/11/2025Q3 2025ENTAEnanta Pharmaceuticals-$1.25-$0.85+$0.40-$0.85$16.21 million$18.31 million8/7/2025Q2 2025CGTXCognition Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A1.541.54ENTAEnanta PharmaceuticalsN/A5.005.00IPHAInnate Pharma2.522.602.60VRCAVerrica PharmaceuticalsN/A1.261.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%ENTAEnanta Pharmaceuticals94.99%IPHAInnate Pharma0.16%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics14.40%ENTAEnanta Pharmaceuticals13.89%IPHAInnate Pharma31.89%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2073.52 million62.94 millionNot OptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableVRCAVerrica Pharmaceuticals409.45 million4.35 millionOptionableVRCA, CGTX, ENTA, and IPHA HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment ...September 3, 2025 | bakersfield.comBArmistice Capital LLC Sells 353,600 Shares of Verrica Pharmaceuticals Inc. $VRCASeptember 3, 2025 | marketbeat.comVerrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.com101,125 Shares in Verrica Pharmaceuticals Inc. $VRCA Acquired by Kovitz Investment Group Partners LLCAugust 26, 2025 | marketbeat.comShort Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Declines By 32.3%August 22, 2025 | marketbeat.comVerrica Posts Profit in Fiscal Q2August 14, 2025 | theglobeandmail.comVerrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of EarningsAugust 13, 2025 | finance.yahoo.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | finanznachrichten.deVerrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comVerrica Pharmaceuticals Regains Nasdaq ComplianceAugust 12, 2025 | msn.comVerrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat EstimatesAugust 12, 2025 | zacks.comVerrica Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | globenewswire.com3VRCA : What to Expect from Verrica Pharmaceuticals's EarningsAugust 11, 2025 | benzinga.comVerrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025August 6, 2025 | globenewswire.comVerrica Pharmaceuticals Implements Reverse Stock SplitAugust 1, 2025 | theglobeandmail.comVerrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...July 12, 2025 | finance.yahoo.comVerrica Pharmaceuticals Inc News (VRCA) - Investing.comJuly 11, 2025 | investing.comVerrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed ...July 11, 2025 | seekingalpha.comVerrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025July 9, 2025 | globenewswire.comVerrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common WartsJuly 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesZillow Group Approaching Key Technical Levels: Is It Time to Buy?By Dan Schmidt | August 23, 2025Amazon Stock Sets Up for Breakout After Bullish CrossoverBy Sam Quirke | August 21, 20253 Reasons Salesforce Is a Bargain Right NowBy Sam Quirke | August 22, 20253 Undervalued Stocks Analysts Are Loving Right Now—Should You?By Gabriel Osorio-Mazilli | August 27, 20253 Cheap Stocks That Shouldn't Be This LowBy Gabriel Osorio-Mazilli | August 25, 2025VRCA, CGTX, ENTA, and IPHA Company DescriptionsCognition Therapeutics NASDAQ:CGTX$1.61 +0.07 (+4.55%) Closing price 04:00 PM EasternExtended Trading$1.69 +0.08 (+4.97%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Enanta Pharmaceuticals NASDAQ:ENTA$7.45 -0.01 (-0.13%) Closing price 04:00 PM EasternExtended Trading$7.44 0.00 (-0.07%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Innate Pharma NASDAQ:IPHA$2.08 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.06 -0.02 (-1.20%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Verrica Pharmaceuticals NASDAQ:VRCA$4.41 -0.53 (-10.73%) Closing price 04:00 PM EasternExtended Trading$4.40 -0.01 (-0.23%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
